Latest News

STAT Plus: AI startups are racing into drug development. Here’s 5 burning questions about which will survive

SAN FRANCISCO — About two years ago, Simon Smith started counting the startups trying to bring artificial intelligence to drug development. Smith, an AI startup executive himself, found about 30 of them. Now? His tally is up to 148.

Smith’s list is incomplete — some companies are still in stealth mode, and others are hard to classify because they straddle the line between AI and traditional biotech — but its rapid growth is a clear sign of an industry on the rise. With big checks from venture capitalists and exploratory deals with drug makers, these startups are trying to cut costs and speed up progress in everything from discovering therapeutic targets to enrolling patients in clinical trials.

Continue to STAT Plus to read the full story…

Source link

Related posts

Doctors, scientists fight superbugs that could kill millions


Groundbreaking law to prohibit sales of animal-tested cosmetics goes into effect on January 1st


STAT Plus: The trials that help drug makers win FDA approval have a median cost of only $19 million


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy